Karim Fizazi, MD, PhD, provides an overview of advances in treatment of metastatic castrate-resistant prostate cancer.
Videos
In the third video of the series, Alicia K. Morgans, MD, MPH, of the Dana-Farber Cancer Institute sheds light on the rapidly developing treatment landscape for advanced prostate cancer.
Alice S. Mims, MD a hematologist at The Ohio State University Comprehensive Cancer Center, discusses testing and actionable mutations in newly diagnosed acute myeloid leukemia.
Richard Anderson, PhD, discusses the effects lymphoma treatments have on fertility.
Drs Shadman and Cohen review clinical trials of zanubrutinib in B-cell lymphomas.
Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, talk about disease progression on BTKi and what mechanisms of resistance can occur.
Michael Bishop, MD, leads the discussion on approaching the first-line management of acute GVHD and the importance of early intervention for patients at risk for the disease.
Expert hematologist-oncologists provide insight on major risk factors for GVHD and associated challenges for treatment.
Theodore W. Laetsch, MD, an attending physician at the Cancer Center at Children’s Hospital of Philadelphia, discusses the safety profile of larotrectinib in thyroid cancer and other solid tumors.
Srdan Verstovsek, MD, PhD, a professor of Medicine and a hematologic oncologist at the University of Texas MD Anderson Cancer Center, discusses the need for new drugs after patients with myelofibrosis are treated with JAK inhibitors.
The panel of experts share their treatment recommendations for a 64-year-old woman with RET wild-type metastatic MTC.
Dr Marcia Brose reviews key efficacy and safety data from the phase 3 ZETA and EXAM clinical trials.
Marcia Brose, MD, presents the case of a 64-year-old woman with RET wild-type metastatic medullary thyroid cancer.
Arndt Vogel, MD, discusses the trial design of IMMUTACE, which is evaluating the efficacy of transarterial chemoembolization in combination with nivolumab for the treatment of intermediate-stage hepatocellular carcinoma.
Catherine Callaghan Coombs, MD, discusses the results of the phase 1/2 BRUIN study of pirtobrutinib in chronic lymphocytic leukemia and small lymphocytic leukemia.
Evanthia Roussos Torres, MD, PhD, discusses the efficacy of entinostat in patients with breast cancer.
An oncologist ruminates on emerging treatment options in follicular lymphoma and offers some clinical pearls.
Alan Skarbnik, MD, explains early relapse in follicular lymphoma and the available treatment options.
An expert describes typical monitoring strategies in follicular lymphoma.
Dr. Alan Skarbnik reviews the use of obinutuzumab-based therapies for follicular lymphoma and highlights data from a phase III study.
A key opinion leader discusses the considerations in choosing induction and maintenance therapy options for follicular lymphoma.
Alan Skarbnik, MD, presents the case of a 60-year-old man with newly diagnosed follicular lymphoma.
Arndt Vogel, MD, the managing senior consultant and professor in the department of Gastroenterology, Hepatology, and Endocrinology, at the Hannover Medical School, discusses the real-world data of immunotherapy combinations in hepatocellular carcinoma.
Alicia K. Morgans, MD, PhD, an associate professor of Medicine at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University Feinberg School of Medicine, gives an overview of androgen receptor therapy in men with non-metastatic castration-resistant prostate cancer.
Dr John DiPersio discusses an early intervention approach to the management of chronic and acute GVHD.
John DiPersio, MD, PhD, and Michael Bishop, MD, define acute and chronic graft-vs-host disease (GVHD).
Michael R. Bishop, MD, discusses chimeric antigen receptor T cells therapy in non-Hodgkin lymphoma.
Kamran A. Ahmed, MD, discusses the data leading up to the phase 1/2 study of radiotherapy followed by intrathecal trastuzumab and pertuzumab for the management of HER2-positive breast cancer with leptomeningeal disease and what impact the study may have on the community oncology space.
Evanthia Roussos Torres, MD, PhD, discusses the study design of the phase 1 trail evaluating entinostat, nivolumab, and ipilimumab in patients with locally advanced or metastatic HER2-negative breast cancer that cannot be removed by surgery.
Dr. Morgans discusses unmet needs and importance of including multidisciplinary teams when treating patients with mCRPC.